News
Recently, tennis legend Serena Williams opened up about using weight-loss medication, aiming to break the ‘stigma’ around ...
1h
Korea JoongAng Daily on MSNWegovy prescriptions near 400,000 as experts concerned over widespread use, health risks
Prescriptions for popular weight-loss drug Wegovy have soared in Korea, reaching nearly 400,000 just eight months after its launch. But doctors and health officials warn of reckless use far beyond the ...
Pricey prescriptions and nagging medical costs are swamping some insurers and employers, which means patients may start ...
3h
Baller Alert on MSNOzempic Could Be Destroying Your Smile — Here’s What Dentists Are Saying
Ozempic users might want to take a good look at their teeth. Dentists across the country are flagging a new complication from GLP-1 drugs like Ozempic and Wegovy: severe oral […] The post Ozempic ...
Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...
Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost ...
Fed Chair Powell's dovish Jackson Hole speech sparks a market rally, while tech dips and earnings drive individual stocks ...
The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...
COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...
In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results